BALTIMORE, July 15, 2011 /PRNewswire/ -- Champions Oncology, Inc., formerly Champions Biotechnology, Inc., (OTC: CSBR): Highlights: Company completes $9.4 million financing during 2011Revenue growth of 41% to $6.9 millionNet loss of $3.8 million; excluding stock based compensation a net loss of $0.7 million* Net loss of ($0.10) per share; net loss excluding stock-based compensation of ($0.02) per share*Cash of $10.5 million at year endAnnual 2011 Financial Results: For its fiscal year 2011, Champions generated revenue of $6.9 million, an increase of $2 million or 41%, compared to fiscal year 2010.

BALTIMORE, Md., April 1, 2011 /PRNewswire/ -- Champions Biotechnology, Inc. (OTC: CSBR) ("Champions" or "the Company") announced today that it has exercised an option to license Irinophore C(TM), a liposomal formulation of Irinotecan, from the BC Cancer Agency ("BCCA") in British Columbia, Canada.

BALTIMORE, March 24, 2011 /PRNewswire/ -- Champions Biotechnology, Inc. (OTC: CSBR) ("Champions") announced today the signing of a technology collaboration agreement with Cephalon, Inc.

BALTIMORE, March 7, 2011 /PRNewswire/ -- Champions Biotechnology, Inc.

BALTIMORE, Jan. 14, 2011 /PRNewswire/ -- Champions Biotechnology, Inc.